Navigation Links
Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
Date:5/8/2012

CRANBURY, N.J., May 8, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its third quarter, fiscal year 2012 financial results on Monday, May 14, 2012 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 14, 2012, which will include discussion of the results of operations in greater detail and an update on corporate developments.Schedule for the Financial Results Press Release, Conference Call / Webcast-

Q3 Fiscal Year 2012 Financial Results Press Release5/14/2012 at 7:30 a.m. ET -

Q3 Fiscal Year 2012 Conference Call-Live

5/14/2012 at 11:00 a.m. ET Domestic Dial-In Number1-888-264-8945International Dial-In Number 

1-913-312-0724Passcode 

8113465-

Q3 Fiscal Year 2012 Conference Call-Replay 

5/14-5/21/2012Domestic Dial-In Number1-888-203-1112International Dial-In Number 

1-719-457-0820Passcode

8113465-

Webcast Live and Replay Accesshttp://www.palatin.com  The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com About Palatin Technologies, Inc.Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at www.palatin.com.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... Calif. , July 6, 2015  Approximately 1% ... is integrated into their chromosomes. These individuals are three ... new study published in one of the nation,s leading ... of Medicine in Canada.  Photo - ... human herpesvirus 6 (HHV-6) causes roseola (also known as ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... cheaper molecular diagnostic tests are key drivers of the global molecular diagnostics market. ... medicine and the introduction of new companion diagnostic tests will increase demand for ...
(Date:7/6/2015)... , July 6, 2015  Viveve Medical, Inc. ("Viveve") (OTCQB: ... Patricia Scheller , Viveve,s Chief Executive Officer, and ... at VirtualInvestorConferences.com on July 9, 2015. , , ... , , , , TIME:     , , ... , , , http://tinyurl.com/viveve   , ...
(Date:7/6/2015)... ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) ... Novella Clinical (Novella), to conduct the phase 3 ... glioblastoma. Novella is a full-service, global clinical research organization ... oncology companies. The ICT-107 phase 3 trial will include ... Europe and Canada , ...
Breaking Biology Technology:Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 3Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 2Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 3Viveve to Webcast Live at VirtualInvestorConferences.com 2Viveve to Webcast Live at VirtualInvestorConferences.com 3ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2
... , , Mark Churchill and Mark Harrison, Thermo Finnigan, , ... , , Bioanalytical Method Validation , ... using , a Thermo Finnigan TSQ Quantum mass spectrometer, , ... , , , , Guidelines on Bioanalytical ...
... , , , , , , ... Beecham Pharmaceuticals , , Metabolite ... Finnigan LCQ , Series of ion trap mass spectrometers. , ... , An integral part of the process by ...
... , , , , Jack Cunniff, Philip Tiller, Michael Harvey, ... , , , , , ... using the Thermo Finnigan LCQ , Series of ion trap mass spectrometers. , ... , For more than five thousand years tea has been used in ...
Cached Biology Technology:Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 2Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 3Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 4Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 5Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 6In-Vitro Metabolism Studies Using Data-Dependent LC/MSn 2In-Vitro Metabolism Studies Using Data-Dependent LC/MSn 3In-Vitro Metabolism Studies Using Data-Dependent LC/MSn 4In-Vitro Metabolism Studies Using Data-Dependent LC/MSn 5In-Vitro Metabolism Studies Using Data-Dependent LC/MSn 6Structural Determination of Flavonoids Using MSn 2Structural Determination of Flavonoids Using MSn 3Structural Determination of Flavonoids Using MSn 4
(Date:6/17/2015)... June 17, 2015  Crossmatch™, a leading provider ... its U.are.U ® 4500 fingerprint readers have ... Eateries, Inc., a San Jose, CA ... increase security, improve accountability and reduce fraud at ... non-repudiable identity confirmation for employee sign in and ...
(Date:6/15/2015)... DALLAS , June 16, 2015 ... Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), ... Worldwide Forecast to 2020" published by MarketsandMarkets, The Natural ... Billion at a CAGR of 18.4% for the forecast ... Tables and   46 F igures spread   ...
(Date:6/10/2015)... , June 10, 2015 ... "3D Sensor Market by Technology (Ultrasound, TOF, Structured ... (consumer Electronics, Entertainment, Automotive) and by Geography - ... by MarketsandMarkets, the market is expected to reach ... of 25.51% between 2015 and 2020. ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 53D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4
... Researchers at the University of Georgia have developed ... ethanol from pretreated pine -- one of the most ... Their research could help biofuels replace gasoline as a ... from woody biomass such as pine, but it is ...
... Human domestication of soybeans is thought to have first occurred ... suggest that cultures in even earlier times and in other ... charred soybean samples from 22 sites in northern China, Japan ... flooring and dumping pits -- with 180 modern charred and ...
... people who initially survive a heart attack, a significant cause ... -- literally, bursting of the heart wall. A ... protein as the key player in the biochemical cascade that ... an Advance Online Publication (AOP) of the journal Nature ...
Cached Biology News:UGA researchers develop 'super' yeast that turns pine into ethanol 2Soybean adoption came early by many cultures, archaeologists say 2Study explains how heart attack can lead to heart rupture 2Study explains how heart attack can lead to heart rupture 3
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
... Dinitro-5,5'-dithiodibenzoic acid , DTNB , Ellman's reagent ... , *CAS-No.: 69-78-3 *Storage: ... with a reactive grouping not present in the ... reagent which will react directly with the product ...
96 Well Base Plate...
... Inhibitor is a recombinant protein that has been ... in the preparation of cDNA by reverse transcription, ... protein synthesis. RNA Safe Inhibitor tightly binds RNases ... range of eukaryotic RNases such as RNase A, ...
Biology Products: